OBAM
ESPR

ODDO BHF Asset Management’s Esperion Therapeutics ESPR Stock Holding History

ODDO BHF Asset Management’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15.8M Buy
+5,000,000
New +$14M 0.73% 48

Other funds holding ESPR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $15.7B AUM 36.4% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
GCIA
Gabelli & Co Investment Advisers Rye, New York $688M AUM 63.4% 1-Year Est. Return

ODDO BHF Asset Management's ESPR Position: Q2 2026 in Review

ODDO BHF Asset Management opened a new position in Esperion Therapeutics (ESPR) in Q2 2026: 5,000,000 shares worth $15.8M. The stake represents 0.73% of the portfolio and ranks #48 among its holdings.

130 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

  • ODDO BHF Asset Management held 5,000,000 shares of Esperion Therapeutics worth $15.8M as of Q2 2026.
  • Esperion Therapeutics was a new ODDO BHF Asset Management position in Q2 2026.
  • Esperion Therapeutics made up 0.73% of ODDO BHF Asset Management's portfolio in Q2 2026, its #48 holding.
  • 130 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on ODDO BHF Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.